Dr. Kirn is an Adjunct Professor of Bioengineering at UC Berkeley. He was a founder at three successful genetic therapy-viral vector companies, led the development of three novel viral vector-based product platforms resulting in over 10 different products, and he designed and led roughly 30 clinical trials (Phase 1-3) involving over 800 patients treated with viral vector gene therapies.